Saveliy has been observed at the Belarusian Research Center for Pediatric Oncology, Hematology, and Immunology since April 2022. In November 2023, hematopoietic bone marrow stem cells were transplanted from unrelated HLA-compatible donors. During January and February 2024, little Savely experienced severe endothelial dysfunction that was life-threatening. From 12.03.2024 to 20.05.2024For pathological purposes, the child received Defibrotide and was given 4 injections of Elizaria (eculizumab). Against the background of the therapy, there was a decrease in vasculitis (inflammation of the vascular wall), a decrease in the intensity of LCD bleeding, a decrease in the need for platelet transfusion, improved laboratory parameters, and positive dynamics according to ultrasound criteria. After discontinuation of the medicine (due to absence from the center), Saveliy again deteriorates with the development of progressive damage to the liver, kidneys, and intestines. The child requires Defitelio, with the potential for ongoing therapy, and Elizaria (eculizumab).
